Bolt Biotherapeutics, Inc.

Equities

BOLT

US0977022039

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 15/05/2026 BST			5-day change	1st Jan Change
4.780 ^USD	-4.40%		+2.36%	-12.58%

05-12	Bolt Biotherapeutics reports first quarter 2026 financial results	RE
05-12	Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Bolt Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt

Published on 03/11/2026

S&P Capital IQ

BOLT BIOTHERAPEUTICS, INC.

-4.40%

Bolt Biotherapeutics, Inc. filed its 10-K on Mar 12, 2026 for the period ending Dec 31, 2025. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Latest news about Bolt Biotherapeutics, Inc.

05-12	Bolt Biotherapeutics reports first quarter 2026 financial results	RE
05-12	Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-12	Bolt Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-11	Bolt Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
01-22	Alert wrongly tagged to Bolt Biotherapeutics Inc withdrawn	RE
01-15	Bolt appoints Olta Andoni as SVP of legal and people to support platform expansion across checkout, identity, and payments	RE
11-12	Bolt Biotherapeutics Q3 collaboration revenue doubles	RE
11-12	Bolt Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
02/10/25	Bolt Biotherapeutics, Inc. Announces Reduction of its Current Workforce by Approximately 20 Employees, or Approximately 50% of its Workforce	CI
02/10/25	Bolt Biotherapeutics, Inc. Provides Update on Ongoing Phase 1 Dose Escalation Study of BDC-4182	CI
02/10/25	Washington Shutdown Continues as US Equity Futures Trade Mixed Ahead of Opening Bell	MT
02/10/25	Top Premarket Decliners	MT
01/10/25	Bolt Biotherapeutics to Cut Workforce by 50%; Cancer Drug Trial Data Expected in Q3 of 2026	MT
01/10/25	Bolt Biotherapeutics Provides Update on BDC-4182	CI
14/08/25	Bolt Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

Chart Bolt Biotherapeutics, Inc.

Duration

Period

BOLT: Dynamic Chart

Company Profile

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Companyâ€™s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Companyâ€™s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.

Employees

Sector

Biotechnology & Medical Research

More about the company